Diaceutics (LON:DXRX) Stock Price Up 1% – Here’s Why

Diaceutics PLC (LON:DXRX)’s stock price traded up 1% during trading on Friday . The stock traded as high as GBX 145 ($1.83) and last traded at GBX 143.90 ($1.82). 39,528 shares were traded during trading, a decline of 68% from the average session volume of 123,055 shares. The stock had previously closed at GBX 142.50 ($1.80).

Wall Street Analysts Forecast Growth

DXRX has been the topic of several recent analyst reports. Canaccord Genuity Group reissued a “buy” rating and issued a GBX 160 ($2.02) target price on shares of Diaceutics in a research note on Tuesday, December 17th. Canaccord Genuity Group reiterated a “buy” rating and issued a GBX 160 ($2.02) price objective on shares of Diaceutics in a research report on Tuesday, December 17th.

Diaceutics Stock Up 1.0 %

The company’s fifty day simple moving average is GBX 136.13 and its 200 day simple moving average is GBX 129.22. The company has a current ratio of 4.85, a quick ratio of 9.92 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of £121.44 million, a P/E ratio of -42.68 and a beta of 0.58.

Insider Activity at Diaceutics

In other news, insider Graham Paterson purchased 11,643 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The shares were bought at an average cost of GBX 138 ($1.74) per share, for a total transaction of £16,067.34 ($20,299.86). 34.30% of the stock is owned by corporate insiders.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.